Nektar Therapeutics | NKTR - Betriebsaufwand

Aktienkurs
72.22
Täglich Wechseln
-2.62 -3.50%
Monatlich
-1.90%
Jährlich
457.45%
Q1 Prognose
70.05




Betriebsaufwand Veränderung Datum
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
ALKERMES USD 326.44M 1.41B 2025-12
Alterity Therapeutics Limited AUD 7.78M 3M 2023-06
Amgen USD 5.9B 773M 2025-12
Baxter International USD 3.19B 554.4M 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Biogen USD 1.88B 81.4M 2025-09
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Cara Therapeutics USD 4.96M 2.38M 2025-03
Cipla INR 60.98B 1.06B 2025-12
Dr.Reddys Laboratories INR 73.6B 1.79B 2025-12
Eisai JPY 199.9B 16.22B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Exelixis USD 362.75M 21.35M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Grifols EUR 1.99B 217.4M 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
MacroGenics USD 53.32M 13.68M 2025-12
Merck USD 10.16B 558M 2025-12
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.8B 61M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Takeda JPY 1.02T 400.98B 2025-12
Teva Pharmaceutical Industries USD 4.22B 812M 2025-12
Xencor USD 81.86M 13.35M 2025-12